ClinicalTrials.gg
Not yet recruitingNCT07943273Updated Nov 17, 2026

Treatment Outcomes and Molecular Prognostic Factors in TP53 Mutated Myeloid Neoplasms

An observational study in AML, TP53 Mutation and Myeldysplastic Syndrome (MDS), sponsored by Centre Hospitalier Universitaire de Nice. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Centre Hospitalier Universitaire de Nice · Observational

How we know

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Study summary

TP53-mutated myeloid neoplasms encompass biologically heterogeneous disorders with frequent cytogenetic abnormalities and poor outcomes. In myelodysplastic neoplasms, TP53 allelic state contributes to clinical phenotype and prognosis. In acute myeloid leukemia (AML) and myelodysplastic syndromes with excess blasts, molecular similarities support studying TP53-associated disease across conventional diagnostic boundaries, although pooling lower-risk and advanced diseases can introduce important clinical heterogeneity. Available therapies improve remission in some patients without reliably producing durable disease control. In a pooled analysis of poor-risk cytogenetic AML with TP53 mutations, azacitidine plus venetoclax increased remission compared with azacitidine alone without a corresponding improvement in survival. A recent molecular analysis of the pivotal CPX-351 trial found that benefit was concentrated in AML with myelodysplasia-related mutations rather than TP53-mutated AML. Allogeneic hematopoietic cell transplantation (HCT) can provide prolonged survival in selected patients, but its outcome depends on biological and clinical context. Retrospective transplant data support integrating VAF and cytogenetics, whereas biological-assignment data in MDS suggest that some patients with TP53 mutations benefit from transplantation. the investigators sought to describe treatment patterns and outcomes in a pooled TP53-associated clinical cohort and to explore cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF. A secondary objective was to describe transplanted patients according to available pre-HCT TP53 VAF and to assess HCT as a time-dependent exposure. Our purpose was hypothesis generation rather than causal ranking of regimens or derivation of a validated transplant-selection rule.

02

Conditions studied

  • AML
  • TP53 Mutation
  • Myeldysplastic Syndrome (MDS)
03

In context

Lead sponsor

Centre Hospitalier Universitaire de Nice is the lead sponsor of 725 studies on the registry; 177 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

TP53 mutated AML and HR-MDS patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • TP53 mutated myeloid AML (> 20% blasts) or HR-SMD
  • Age: Age ≥ 18 years
  • Allo-HCT was permitted.
  • Available NGS analysis at diagnosis
  • TP53 VAF > 2%
  • Myeloid sarcoma were permitted
  • Patients received at least 1 treatment line

Exclusion criteria

Exclusion Criteria:

  • TP53 mutations class 1 or 2 or 3 (American College of Medical Genetic and Genomics
  • Patients alive at the start of the study who did not receive study information or who objected to the collection of data
  • TP53 CCUS or CHIP
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • TP53 mutated myeloid neoplasms from Nice University Hospital

    We sought to describe treatment patterns and outcomes in a pooled TP53-associated clinical cohort and to explore cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF. A secondary objective was to describe transplanted patients according to available pre-HCT TP53 VAF and to assess HCT as a time-dependent exposure

    Other: Treatment outcomes and molecular prognostic

  • TP53 mutated myeloid neoplasms from Saint-Louis University Hospital

    We sought to describe treatment patterns and outcomes in a pooled TP53-associated clinical cohort and to explore cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF. A secondary objective was to describe transplanted patients according to available pre-HCT TP53 VAF and to assess HCT as a time-dependent exposure

    Other: Treatment outcomes and molecular prognostic

Interventions

  • OtherTreatment outcomes and molecular prognostic

    We sought to describe treatment patterns and outcomes in a pooled TP53-associated clinical cohort and to explore cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF. A secondary objective was to describe transplanted patients according to available pre-HCT TP53 VAF and to assess HCT as a time-dependent exposure

  • OtherTreatment outcomes and molecular prognostic

    We sought to describe treatment patterns and outcomes in a pooled TP53-associated clinical cohort and to explore cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF. A secondary objective was to describe transplanted patients according to available pre-HCT TP53 VAF and to assess HCT as a time-dependent exposure

06

What researchers measure

Primary outcomes

  1. Description of clinical outcomes according to treatment patterns

    We sought to describe treatment patterns in fonction of outcomes in a pooled TP53-associated clinical cohort

    Time frame: Time from first administration of induction chemotherapy to death from any cause, assessed up to 01/01/2027

Secondary outcomes

  1. HCT as a time-dependent exposure.

    Description of transplanted patients to assess HCT as a time-dependent exposure.

    Time frame: Time from date of diagnosis then HCT to date of relapse or death from any cause, assessed up to 01/01/2027

  2. Pre-HCT TP53 variant allelic frequency (VAF)

    Variant allelic fraquency of TP53 at diagnosis

    Time frame: Baseline

  3. Molecular prognostic

    To explore survival impact of cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF

    Time frame: Baseline

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2027; primary completion for Jun 2027, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2026
First posted
Nov 17, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07943273
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Thomas CLUZEAU
Contact
cluzeau.t@chu-nice.fr
0492039025 ext. +33
Caroline Fileni
Contact
fileni.c@chu-nice.fr

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion